Core Viewpoint - Zhonghui Biotech-B (02627) has seen a stock increase of over 7%, currently at 46.5 HKD, with a trading volume of 18.84 million HKD, following recommendations from health authorities for annual flu vaccinations for all individuals over 6 months old without contraindications [1] Group 1: Product and Market Performance - Huiru Kexin is the first and only quadrivalent subunit flu vaccine in China, offering comprehensive protection, high purity of antigen components, and lower risk of adverse reactions compared to split vaccines [1] - The product was approved for domestic market launch in 2023, targeting individuals aged 3 and above, with plans to expand to those over 6 months old by 2025 [1] - Revenue for 2024 is projected to reach 260 million RMB, representing a year-on-year growth of 398% [1] Group 2: Research and Development - The company has developed a comprehensive vaccine development support platform and proprietary technology platform, aligning with international trends through years of research [1] - The company is advancing both innovative vaccine research and traditional vaccine upgrades, creating a rich pipeline of vaccines [1] - In addition to the quadrivalent flu vaccine and human diploid cell rabies vaccine, the company is actively developing 11 other vaccines to address market gaps [1]
中慧生物-B涨超7% 国内流感疫苗潜在增长空间广阔